Literature DB >> 8792390

The effect of recombinant human growth hormone on responses to alloantigens in the pediatric transplant patient.

M R Benfield1, A Vail, F B Waldo, R P Bucy, E C Kohaut.   

Abstract

Recombinant human growth hormone (rhGH) improves growth in children after renal transplantation, but may be associated with augmented immune responses. We previously demonstrated that rhGH augments proliferative and cytotoxic responses and interferon-gamma (IFN-gamma) mRNA expression during a mixed leukocyte culture (MLC). In this study, we evaluated 12 pediatric patients after receiving a renal allograft from one of their parents. Peripheral blood mononuclear cells (PBMC) were isolated from patients and cultured with either donor or unrelated third-party PBMC in an MLC. Patients developed significant donor-specific hyporesponsiveness (DSH), however, no correlation was seen between the amount of DSH and graft function. Of the 12 patients, 2 developed augmented responses in the presence of rhGH. rhGH augments proliferation, cytotoxicity, and IFN-gamma expression during an MLC. Some patients develop increased responses to donor-specific alloantigens after renal transplantation. Further study is needed to better determine the significance of this finding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792390     DOI: 10.1007/bf00866759

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  Growth hormone, lymphocytes and macrophages.

Authors:  K W Kelley
Journal:  Biochem Pharmacol       Date:  1989-03-01       Impact factor: 5.858

2.  Recombinant human growth hormone augments responses in the mixed leukocyte culture.

Authors:  M R Benfield; A Vail; D A Weigent
Journal:  Transplant Proc       Date:  1994-02       Impact factor: 1.066

3.  Demonstration of growth hormone (GH) receptor-associated tyrosine kinase activity in multiple GH-responsive cell types.

Authors:  S E Stred; J R Stubbart; L S Argetsinger; J A Shafer; C Carter-Su
Journal:  Endocrinology       Date:  1990-11       Impact factor: 4.736

4.  Expression of immunoreactive growth hormone in leukocytes in vivo.

Authors:  J B Baxter; J E Blalock; D A Weigent
Journal:  J Neuroimmunol       Date:  1991-07       Impact factor: 3.478

5.  A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients.

Authors:  N L Reinsmoen; D Kaufman; A Matas; D E Sutherland; J S Najarian; F H Bach
Journal:  Transplantation       Date:  1990-11       Impact factor: 4.939

6.  Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity.

Authors:  N L Reinsmoen; A J Matas
Journal:  Transplantation       Date:  1993-05       Impact factor: 4.939

7.  The use of cyclosporine in living-related renal transplantation. Donor-specific hyporesponsiveness and steroid withdrawal.

Authors:  S M Flechner; R H Kerman; C T Van Buren; L Epps; B D Kahan
Journal:  Transplantation       Date:  1984-12       Impact factor: 4.939

Review 8.  Growth hormone in the treatment of growth failure in children after renal transplantation.

Authors:  M R Benfield; K L Parker; F B Waldo; S L Overstreet; E C Kohaut
Journal:  Kidney Int Suppl       Date:  1993-10       Impact factor: 10.545

  8 in total
  2 in total

1.  Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology.

Authors:  H Maxwell; L Rees
Journal:  Arch Dis Child       Date:  1998-12       Impact factor: 3.791

Review 2.  Longitudinal growth in children following kidney transplantation: from conservative to pharmacological strategies.

Authors:  Tim Ulinski; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2006-05-10       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.